Octagon Capital Advisors
Octagon Capital Advisors reported 26 stocks worth $1.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DNTH (16.5%), DFTX (12.7%) and ABVX (12.2%). Compared with Q1 2026, the fund opened new positions in SMMT, ANL and FTH, added to DFTX, ABVX and TSHA, trimmed DNTH, KYMR and OCUL and sold out of BBOT, LXEO and CATX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  DNTH Dianthus Therapeutics Inc | $180M | 16.5% | 1.8M | −105K (−5%) | 8 of 8 | |
| 2 |  DFTX Definium Therapeutics Inc | $139M | 12.7% | 3M | +510K (+21%) | 2 of 8 | |
| 3 |  ABVX Abivax SA | $132M | 12.2% | 993K | +316K (+47%) | 6 of 8 | |
| 4 |  COGT Cogent Biosciences Inc | $90.9M | 8.3% | 2.4M | No change | 8 of 8 | |
| 5 |  ALMS Alumis Inc | $79.7M | 7.3% | 2.8M | No change | 3 of 8 | |
| 6 |  AVBP Arrivent Biopharma Inc | $68.5M | 6.3% | 2M | No change | 8 of 8 | |
| 7 |  TSHA Taysha Gene Therapies Inc | $66M | 6.1% | 9.7M | +833K (+9%) | 8 of 8 | |
| 8 |  BIOA Bioage Labs Inc | $42.8M | 3.9% | 1.7M | No change | 3 of 8 | |
| 9 |  MIRM Mirum Pharmaceuticals Inc | $39.7M | 3.6% | 339K | No change | 2 of 8 | |
| 10 |  KYMR Kymera Therapeutics Inc | $35.5M | 3.3% | 310K | −115K (−27%) | 5 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CENTESSA PHARMACEUTICALS PLC | $29.8M | 750K |
KALVISTA PHARMACEUTICALS INC | $29.2M | 1.4M |
TERNS PHARMACEUTICALS INC | $27.9M | 530K |
 BBOT Bridgebio Oncology Therapeut | $6.4M | 719K |
 LXEO Lexeo Therapeutics Inc | $6.3M | 1.1M |
🔒 Free account: see all 7.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 ERAS Erasca Inc | Call | $23M | 1.3M | +1,255,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Octagon Capital Advisors 13F FAQ
What does Octagon Capital Advisors own?
Octagon Capital Advisors reported 26 stocks worth $1.1B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DNTH (16.5%), DFTX (12.7%) and ABVX (12.2%). The table above lists every position in the filing (the top 10 without an account).
What did Octagon Capital Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 4 new positions, 4 added to, 6 trimmed and 7 sold out. New positions include SMMT, ANL and FTH. It sold all of BBOT, LXEO and CATX.
When will Octagon Capital Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Octagon Capital Advisors's portfolio worth?
The Q2 2026 filing reports $1.1B in US stocks ($1.1B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.